Clinical Trial Update: Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing inhaled LAMA, LAMA+LABA, and ICS+LABA in patients with COPD and bronchiectasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• ICS+LABA (inhaled corticosteroid + long-acting beta-agonist)
• LAMA (long-acting muscarinic antagonist)
• LAMA+LABA (LAMA+LABA)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: COPD, Bronchiectasis | Phase 4 | Status: UNKNOWN